Companies Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals (REGN): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Regeneron Pharmaceuticals, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers1st pct.Of 11 peer CEOs
CEO pay, last three years
- $8,184,338FY2023
- $6,823,034FY2024
- $7,280,549FY2025
CEO total pay was $7,280,549 in fiscal 2025, up from $6,823,034 in fiscal 2024.
FY2025: salary $1,979,922 · bonus $0
Executives and directors
Andrew Murphy · EVPJoseph LaRosa · General CounselChristopher Fenimore · CFODaniel Van Plew · EVPGeorge Yancopoulos · PresidentLeonard Schleifer · CEOArthur F. Ryan · Independent DirectorChristine A. Poon · Lead Independent DirectorCraig B. Thompson · Independent DirectorDavid P. Schenkein · Independent DirectorGeorge L. Sing · Independent DirectorHuda Y. Zoghbi · Independent DirectorJoseph L. Goldstein · Independent DirectorMichael S. Brown · Independent DirectorN. Anthony Coles · Independent Director
Frequently asked questions
Who was the highest-paid executive at Regeneron Pharmaceuticals, Inc in fiscal 2025?
As disclosed, Daniel Van Plew (Executive Vice President and General Manager, Industrial Operations and Product Supply) was the highest-paid executive at Regeneron Pharmaceuticals, Inc in fiscal 2025, with total compensation of $8,780,263.
How does Regeneron Pharmaceuticals, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Leonard Schleifer's total compensation ranked at the 1st percentile of Regeneron Pharmaceuticals, Inc's disclosed peer group.
What is Regeneron Pharmaceuticals, Inc's CEO-to-median employee pay ratio?
As disclosed, Regeneron Pharmaceuticals, Inc's CEO-to-median employee pay ratio was 42:1.
How did shareholders vote on Regeneron Pharmaceuticals, Inc's executive compensation?
As disclosed, 93.33% of shareholders supported Regeneron Pharmaceuticals, Inc's executive compensation in the latest say-on-pay vote.
How much does Regeneron Pharmaceuticals, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Regeneron Pharmaceuticals, Inc reported total board compensation of $2,655,946 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Van Plew | $983,382 | $0 | $2,699,728 | $4,049,757 | $965,189 | $0 | $82,207 | $8,780,263 |
| Executive Vice President and General Manager, Industrial Operations and Product Supply | ||||||||
| Andrew Murphy | 819,672 | 0 | 2,699,728 | 4,049,757 | 815,164 | 0 | 92,798 | 8,477,119 |
| Executive Vice President, Co-Chief Scientific Officer | ||||||||
| Joseph LaRosa | 916,062 | 1,000,000 | 1,799,334 | 2,699,810 | 911,024 | 0 | 132,740 | 7,458,970 |
| Executive Vice President, General Counsel and Secretary | ||||||||
| Leonard Schleifer | 1,979,922 | 0 | — | — | 3,682,655 | 0 | 1,617,972 | 7,280,549 |
| Board co-Chair, President and Chief Executive Officer | ||||||||
| Christopher Fenimore | 725,000 | 0 | 2,199,751 | 3,299,977 | 721,013 | 0 | 39,623 | 6,985,364 |
| Executive Vice President, Finance and Chief Financial Officer | ||||||||
| George Yancopoulos | 1,979,922 | 0 | — | — | 3,682,655 | 0 | 1,286,892 | 6,949,469 |
| Board co-Chair, President and Chief Scientific Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel Van Plew | $8,780,263 | $8,655,178 | $8,760,149 | ↑ +125,085 |
| Andrew Murphy | 8,477,119 | 8,363,257 | 8,429,311 | ↑ +113,862 |
| Joseph LaRosa | 7,458,970 | — | — | — |
| Leonard Schleifer | 7,280,549 | 6,823,034 | 8,184,338 | ↑ +457,515 |
| Christopher Fenimore | 6,985,364 | 6,268,252 | — | ↑ +717,112 |
| George Yancopoulos | 6,949,469 | 6,796,783 | 7,759,830 | ↑ +152,686 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The starting premise for compensation at Regeneron is that our compensation practices must be "fit for purpose" and reinforce the long-term outlook necessary to fulfill the Company's mission - to turn rigorous scientific research into groundbreaking medicines. This mission is the ultimate driver of sustainable, long-term value creation for our shareholders.
| CEO STI target (% of salary) | 120% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Andrew Murphy | RSU | 2025-12-05 | — | — | 3,715 | — | $2,699,728 |
| Andrew Murphy | OPTION | 2025-12-05 | — | — | 18,315 | — | 4,049,757 |
| Christopher Fenimore | OPTION | 2025-12-05 | — | — | 14,924 | — | 3,299,977 |
| Daniel Van Plew | RSU | 2025-12-05 | — | — | 3,715 | — | 2,699,728 |
| Joseph LaRosa | RSU | 2025-12-05 | — | — | 2,476 | — | 1,799,334 |
| Daniel Van Plew | OPTION | 2025-12-05 | — | — | 18,315 | — | 4,049,757 |
| Christopher Fenimore | RSU | 2025-12-05 | — | — | 3,027 | — | 2,199,751 |
| Joseph LaRosa | OPTION | 2025-12-05 | — | — | 12,210 | — | 2,699,810 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Andrew Murphy | $2,699,728 | $0 | $4,049,757 | 0.0% |
| Christopher Fenimore | 2,199,751 | 0 | 3,299,977 | 0.0% |
| Daniel Van Plew | 2,699,728 | 0 | 4,049,757 | 0.0% |
| Joseph LaRosa | 1,799,334 | 0 | 2,699,810 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Fenimore | RSU | 963 | — | $743,311 |
| Joseph LaRosa | RSU | 1,066 | — | 822,813 |
| Christopher Fenimore | RSU | 1,185 | — | 914,666 |
| Joseph LaRosa | RSU | 1,376 | — | 1,062,093 |
| Christopher Fenimore | RSU | 1,599 | — | 1,234,220 |
| Andrew Murphy | RSU | 1,599 | — | 1,234,220 |
| Christopher Fenimore | RSU | 1,899 | — | 1,465,781 |
| Andrew Murphy | RSU | 2,064 | — | 1,593,140 |
| Joseph LaRosa | RSU | 2,332 | — | 1,800,001 |
| Joseph LaRosa | RSU | 2,476 | — | 1,911,150 |
| Christopher Fenimore | RSU | 2,591 | — | 1,999,915 |
| Christopher Fenimore | RSU | 3,027 | — | 2,336,450 |
| Christopher Fenimore | RSU | 3,499 | — | 2,700,773 |
| Andrew Murphy | RSU | 3,499 | — | 2,700,773 |
| Christopher Fenimore | RSU | 3,715 | — | 2,867,497 |
| Andrew Murphy | RSU | 3,715 | — | 2,867,497 |
| Joseph LaRosa | PSU | 7,250 | — | 5,596,057 |
| Christopher Fenimore | PSU | 7,766 | — | 5,994,342 |
| Christopher Fenimore | PSU | 10,712 | — | 8,268,271 |
| Andrew Murphy | PSU | 10,877 | — | 8,395,630 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Christine A. PoonIndependent · Lead Independent Director · Compensation Committee (Chair) · Corporate Governance and Compliance Committee | $170,000 | $119,415 | $480,552 | — | $5,449 | $775,416 |
| Michael S. BrownIndependent · Technology Committee | 120,000 | 119,415 | 480,552 | — | 10,449 | 730,416 |
| George L. SingIndependent · Audit Committee (Chair) | 120,000 | 119,415 | 480,552 | — | 10,449 | 730,416 |
| Arthur F. RyanIndependent · Audit Committee | 120,000 | 119,415 | 480,552 | — | 5,449 | 725,416 |
| Huda Y. ZoghbiIndependent · Technology Committee | 110,000 | 119,415 | 480,552 | — | 10,449 | 720,416 |
| N. Anthony ColesIndependent · Audit Committee · Compensation Committee | 107,411 | 119,415 | 480,552 | — | 10,449 | 717,827 |
| Joseph L. GoldsteinIndependent · Corporate Governance and Compliance Committee · Technology Committee | 110,000 | 119,415 | 480,552 | — | 5,449 | 715,416 |
| Bonnie L. BasslerIndependent · Technology Committee | 110,000 | 119,415 | 480,552 | — | 5,449 | 715,416 |
| Craig B. ThompsonIndependent · Corporate Governance and Compliance Committee | 103,021 | 119,415 | 480,552 | — | 2,182 | 705,170 |
| David P. SchenkeinIndependent · Compensation Committee | 103,021 | 119,415 | 480,552 | — | 1,577 | 704,565 |
| Kathryn GuariniIndependent · Audit Committee | 100,000 | 119,415 | 480,552 | — | 1,577 | 701,544 |
| George D. YancopoulosEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
| Leonard S. SchleiferEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $600,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 10,000 / 10,000 |
| Stock ownership guideline | $1,950,000 |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,273,453 |
| Equity awards (grant-date value) | $1,313,565 |
| All other compensation | $68,928 |
| Total cost of the board | $2,655,946 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Regeneron Pharmaceuticals as a peer
Companies that benchmark against REGN
20 companies name REGN as a compensation peer
The list of companies that name REGN as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
VRTX Vertex Pharmaceuticals IncorporatedALNY Alnylam Pharmaceuticals, Inc.BMY Bristol-Myers Squibb CompanyGILD Gilead Sciences, Inc.ABBV AbbVie Inc.BMRN BioMarin Pharmaceutical Inc.AMGN Amgen Inc.MRK Merck & Co., Inc.BIIB Biogen Inc.LLY Eli Lilly and CompanyINCY Incyte Corporation
Peer reciprocity
The companies Regeneron Pharmaceuticals, Inc names as compensation peers that name it back in their own disclosed peer groups.
Alnylam Pharmaceuticals, Inc. (ALNY)163Bristol-Myers Squibb Company (BMY)164Gilead Sciences, Inc. (GILD)165BioMarin Pharmaceutical Inc. (BMRN)166Amgen Inc. (AMGN)167
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company | 2025 | David Ricks | $1,700,000 | $23,325,000 | $0 | $6,485,500 | $36,698,337 |
| 2 | AbbVie Inc. | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 3 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 4 | Gilead Sciences, Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 5 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 6 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 7 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 8 | Bristol-Myers Squibb Company | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 9 | Vertex Pharmaceuticals Incorporated | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 10 | Merck & Co., Inc. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 11 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 12 | Regeneron Pharmaceuticals, Inc | 2025 | Leonard Schleifer | 1,979,922 | — | — | 3,682,655 | 7,280,549 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| AbbVie Inc. | not disclosed | PSU 40 · PRSU 40 · Option 20 | Yes — Relative TSR | Semler Brossy |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Bristol-Myers Squibb Company | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| Gilead Sciences, Inc. | 180% | PSU 50 · Option 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Incyte Corporation | 138.6% | PSU 60 · RSU 20 · Option 20 | Yes — relative total shareholder return (TSR) | Aon |
| Merck & Co., Inc. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Vertex Pharmaceuticals Incorporated | not disclosed | PSU 55 · RSU 45 | No | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-12 | 96,469,374 | 6,898,268 | 105,512 | 93.33% | Passed |
| 2025 | 2025-06-13 | 98,781,758 | 7,100,590 | 111,931 | 93.29% | Passed |
| 2024 | 2024-06-14 | 106,667,264 | 5,579,814 | 207,463 | 95.03% | Passed |
| 2023 | 2023-06-09 | 97,786,842 | 14,490,406 | 240,046 | 87.09% | Passed |
| 2022 | 2022-06-10 | 97,837,229 | 13,595,339 | 169,288 | 87.8% | Passed |
| 2020 | 2020-06-12 | 81,690,302 | 34,709,497 | 100,771 | 70.18% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-12 | 93.33%a |
| 2025 | 2025-06-13 | 93.29%b |
| 2024 | 2024-06-14 | 95.03%c |
a. Approved under the standard stated in the filing — “Proposal No. 3: Say-on-Pay Non-binding, advisory proposal. We will consider the matter approved if it receives the affirmative vote of a majority of the votes cast. No effect - not considered votes cast on this proposal No - brokers without voting instructions will not be able to vote on this proposal”.
b. Approved under the standard stated in the filing — “Proposal No. 3: Say-on-Pay -- Non-binding, advisory proposal. We will consider the matter approved if it receives the affirmative vote of a majority of the votes cast | Abstentions: No effect – not considered votes cast on this proposal”.
c. Approved under the standard stated in the filing — “Non-binding, advisory proposal. We will consider the matter approved if it receives the affirmative vote of a majority of the votes cast | Abstentions: No effect – not considered votes cast on this proposal”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 42 : 1 |
|---|---|
| CEO total compensation | $7,280,549 |
| Median employee compensation | $174,138 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Arthur F. Ryan | Director | 2026-05-01 | D | 2 | $714 | $1,428 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 2 | 711 | 1,422 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 6 | 709 | 4,257 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 4 | 707 | 2,830 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 7 | 707 | 4,947 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 14 | 706 | 9,878 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 15 | 704 | 10,564 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 24 | 703 | 16,883 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 15 | 702 | 10,537 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 5 | 702 | 3,509 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 1 | 712 | 712 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 5 | 711 | 3,557 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-07-02 | D | 200 | 650 | 130,030 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-08-10 | D | 800 | 800 | 640,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-08-10 | A | 400 | 719 | 287,748 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-10 | — | 1,200 | — | — | 2 insiders, 2 accrual rows | ||
| Huda Y. Zoghbi | Director | 2026-08-10 | A | 800 | 377 | 301,352 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-08-10 | D | 400 | 800 | 320,000 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-08-18 | A | 6,283 | 382 | 2,399,603 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-08-18 | D | 4,599 | 813 | 3,741,149 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-08-18 | D | 6,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-08-19 | A | 12,282 | 382 | 4,690,741 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-08-19 | D | 12,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-08-19 | D | 9,019 | 830 | 7,487,123 | Common | Form 4 ↗ |
| Marion McCourt | EVP Commercial | 2026-09-02 | D | 1,215 | 850 | 1,032,750 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-09-02 | D | 400 | 850 | 340,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-09-02 | A | 400 | 719 | 287,748 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-02 | — | 400 | — | — | 1 insider, 1 accrual row | ||
| Marion McCourt | EVP Commercial | 2026-09-03 | D | 1,131 | 857 | 969,708 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-13 | A | 17,000 | 382 | 6,492,640 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-13 | D | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-13 | D | 12,853 | 755 | 9,698,617 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 463 | 781 | 361,432 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 454 | 779 | 353,503 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 38 | 778 | 29,555 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 66 | 776 | 51,236 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 121 | 774 | 93,712 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 211 | 773 | 163,010 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 105 | 768 | 80,675 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 192 | 767 | 147,339 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 271 | 765 | 207,421 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 55 | 763 | 41,941 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 27 | 761 | 20,557 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 74 | 761 | 56,288 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 14 | 760 | 10,639 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 224 | 773 | 173,242 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 12 | 770 | 9,242 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 16 | 758 | 12,123 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 35 | 756 | 26,457 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 6 | 754 | 4,523 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 50 | 781 | 39,074 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 380 | 780 | 296,244 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 376 | 775 | 291,573 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 283 | 772 | 218,351 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 127 | 769 | 97,701 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 279 | 766 | 213,845 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 219 | 764 | 167,404 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 25 | 764 | 19,094 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 24 | 758 | 18,196 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-30 | — | 2,329 | — | — | 2 insiders, 2 accrual rows | ||
| Kathryn Guarini | Director | 2026-10-30 | D | 400 | 900 | 360,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-10-30 | A | 400 | 719 | 287,748 | Common | Form 4 ↗ |
| Marion McCourt | EVP Commercial | 2026-10-30 | D | 1,132 | 869 | 984,195 | Common | Form 4 ↗ |
| Michael S. Brown | Director | 2026-10-30 | D | 1,929 | 875 | 1,687,875 | Common | Form 4 ↗ |
| Michael S. Brown | Director | 2026-10-30 | A | 1,929 | 726 | 1,400,242 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 3,939 | 965 | 3,802,750 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 8,686 | 951 | 8,256,043 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 12,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 527 | 966 | 509,140 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | D | 15 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | D | 4,243 | 951 | 4,032,972 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | A | 6,000 | 382 | 2,291,520 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 7,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 201 | 971 | 195,233 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 937 | 971 | 909,368 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 3,203 | 970 | 3,105,309 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 2,499 | 969 | 2,420,481 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 772 | 967 | 746,817 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 7,439 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 7,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 1,040 | 967 | 1,005,753 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 1,522 | 966 | 1,470,663 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 7,073 | 965 | 6,828,133 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 2,670 | 965 | 2,575,402 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 4,338 | 963 | 4,179,533 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 2,522 | 963 | 2,427,702 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 540 | 962 | 519,399 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 1,224 | 961 | 1,175,738 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 200 | 970 | 194,036 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | D | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | A | 7,830 | 377 | 2,949,483 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | A | 12,283 | 382 | 4,691,123 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | A | 7,439 | 381 | 2,833,887 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | A | 7,830 | 377 | 2,949,483 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 218 | 967 | 210,749 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-11-03 | D | 1,054 | 0 | 0 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | D | 7,439 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | D | 500 | 971 | 485,530 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | D | 6,939 | 970 | 6,733,744 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | A | 7,439 | 381 | 2,833,887 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-11-04 | — | 3,883 | — | — | 1 insider, 3 accrual rows | ||
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 179 | 951 | 170,186 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 35 | 946 | 33,096 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 108 | 944 | 101,976 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 529 | 944 | 499,127 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 1,215 | 942 | 1,144,907 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 982 | 942 | 924,632 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 575 | 940 | 540,765 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 439 | 940 | 412,471 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | A | 905 | 492 | 445,260 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | A | 1,478 | 645 | 952,630 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | A | 1,500 | 727 | 1,089,795 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 116 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Arthur F. Ryan | Director | 2026-05-01 | D | 2 | $714 | $1,428 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 2 | 711 | 1,422 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 6 | 709 | 4,257 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 4 | 707 | 2,830 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 7 | 707 | 4,947 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 14 | 706 | 9,878 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 15 | 704 | 10,564 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 24 | 703 | 16,883 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 15 | 702 | 10,537 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 5 | 702 | 3,509 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 1 | 712 | 712 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-05-01 | D | 5 | 711 | 3,557 | Common | Form 4 ↗ |
| Arthur F. Ryan | Director | 2026-07-02 | D | 200 | 650 | 130,030 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-08-10 | D | 800 | 800 | 640,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-08-10 | A | 400 | 719 | 287,748 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-08-10 | D | 800 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-08-10 | A | 800 | 377 | 301,352 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-08-10 | D | 400 | 800 | 320,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-08-10 | D | 400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-08-18 | A | 6,283 | 382 | 2,399,603 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-08-18 | D | 4,599 | 813 | 3,741,149 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-08-18 | D | 6,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-08-19 | A | 12,282 | 382 | 4,690,741 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-08-19 | D | 12,282 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-08-19 | D | 9,019 | 830 | 7,487,123 | Common | Form 4 ↗ |
| Marion McCourt | EVP Commercial | 2026-09-02 | D | 1,215 | 850 | 1,032,750 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-09-02 | D | 400 | 850 | 340,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-09-02 | A | 400 | 719 | 287,748 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-09-02 | D | 400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marion McCourt | EVP Commercial | 2026-09-03 | D | 1,131 | 857 | 969,708 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-13 | A | 17,000 | 382 | 6,492,640 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-13 | D | 17,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-13 | D | 12,853 | 755 | 9,698,617 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 463 | 781 | 361,432 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 454 | 779 | 353,503 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 38 | 778 | 29,555 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 66 | 776 | 51,236 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 121 | 774 | 93,712 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 211 | 773 | 163,010 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 105 | 768 | 80,675 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 192 | 767 | 147,339 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 271 | 765 | 207,421 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 55 | 763 | 41,941 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 27 | 761 | 20,557 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 74 | 761 | 56,288 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 14 | 760 | 10,639 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 224 | 773 | 173,242 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 12 | 770 | 9,242 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 16 | 758 | 12,123 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 35 | 756 | 26,457 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 6 | 754 | 4,523 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 50 | 781 | 39,074 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 380 | 780 | 296,244 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 376 | 775 | 291,573 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 283 | 772 | 218,351 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 127 | 769 | 97,701 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 279 | 766 | 213,845 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 219 | 764 | 167,404 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 25 | 764 | 19,094 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-10-14 | D | 24 | 758 | 18,196 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-10-30 | D | 400 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-10-30 | D | 400 | 900 | 360,000 | Common | Form 4 ↗ |
| Kathryn Guarini | Director | 2026-10-30 | A | 400 | 719 | 287,748 | Common | Form 4 ↗ |
| Marion McCourt | EVP Commercial | 2026-10-30 | D | 1,132 | 869 | 984,195 | Common | Form 4 ↗ |
| Michael S. Brown | Director | 2026-10-30 | D | 1,929 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael S. Brown | Director | 2026-10-30 | D | 1,929 | 875 | 1,687,875 | Common | Form 4 ↗ |
| Michael S. Brown | Director | 2026-10-30 | A | 1,929 | 726 | 1,400,242 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 3,939 | 965 | 3,802,750 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 8,686 | 951 | 8,256,043 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 12,283 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | D | 527 | 966 | 509,140 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | D | 15 | 0 | 0 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | D | 4,243 | 951 | 4,032,972 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | A | 6,000 | 382 | 2,291,520 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 7,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 201 | 971 | 195,233 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 937 | 971 | 909,368 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 3,203 | 970 | 3,105,309 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 2,499 | 969 | 2,420,481 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 772 | 967 | 746,817 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 7,439 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 7,830 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 1,040 | 967 | 1,005,753 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 1,522 | 966 | 1,470,663 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 7,073 | 965 | 6,828,133 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 2,670 | 965 | 2,575,402 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 4,338 | 963 | 4,179,533 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 2,522 | 963 | 2,427,702 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 540 | 962 | 519,399 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 1,224 | 961 | 1,175,738 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | D | 200 | 970 | 194,036 | Common | Form 4 ↗ |
| Christopher Fenimore | EVP Finance CFO | 2026-11-02 | D | 6,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | A | 7,830 | 377 | 2,949,483 | Common | Form 4 ↗ |
| Joseph LaRosa | EVP General Counsel and Secret | 2026-11-02 | A | 12,283 | 382 | 4,691,123 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | A | 7,439 | 381 | 2,833,887 | Common | Form 4 ↗ |
| George L. Sing | Director | 2026-11-02 | A | 7,830 | 377 | 2,949,483 | Common | Form 4 ↗ |
| Christine A. Poon | Director | 2026-11-02 | D | 218 | 967 | 210,749 | Common | Form 4 ↗ |
| Andrew Murphy | Co-Chief Scientific Officer | 2026-11-03 | D | 1,054 | 0 | 0 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | D | 7,439 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | D | 500 | 971 | 485,530 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | D | 6,939 | 970 | 6,733,744 | Common | Form 4 ↗ |
| Huda Y. Zoghbi | Director | 2026-11-03 | A | 7,439 | 381 | 2,833,887 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 1,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 1,478 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 905 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 179 | 951 | 170,186 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 35 | 946 | 33,096 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 108 | 944 | 101,976 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 529 | 944 | 499,127 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 1,215 | 942 | 1,144,907 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 982 | 942 | 924,632 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 575 | 940 | 540,765 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | D | 439 | 940 | 412,471 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | A | 905 | 492 | 445,260 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | A | 1,478 | 645 | 952,630 | Common | Form 4 ↗ |
| Jason Pitofsky | SVP Controller | 2026-11-04 | A | 1,500 | 727 | 1,089,795 | Common | Form 4 ↗ |
Sources (167 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Daniel Van Plew. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 8,780,263. View filing ↗
- Section 01, Andrew Murphy. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 8,477,119. View filing ↗
- Section 01, Joseph LaRosa. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 7,458,970. View filing ↗
- Section 01, Leonard Schleifer. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 7,280,549. View filing ↗
- Section 01, Christopher Fenimore. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 6,985,364. View filing ↗
- Section 01, George Yancopoulos. DEF 14A, filed 2026-04-24. Section “2025 Summary Compensation Table”. As printed: 6,949,469. View filing ↗
- Section 03, Andrew Murphy RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Andrew Murphy OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Fenimore OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Van Plew RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph LaRosa RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Van Plew OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Fenimore RSU. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Joseph LaRosa OPTION. DEF 14A, filed 2026-04-24. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-24. Section “CEO Pay Ratio”. As printed: 42 : 1. View filing ↗
- Section 08, Christine A. Poon. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 775,416. View filing ↗
- Section 08, Michael S. Brown. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 730,416. View filing ↗
- Section 08, George L. Sing. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 730,416. View filing ↗
- Section 08, Arthur F. Ryan. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 725,416. View filing ↗
- Section 08, Huda Y. Zoghbi. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 720,416. View filing ↗
- Section 08, N. Anthony Coles. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 717,827. View filing ↗
- Section 08, Joseph L. Goldstein. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 715,416. View filing ↗
- Section 08, Bonnie L. Bassler. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 715,416. View filing ↗
- Section 08, Craig B. Thompson. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 705,170. View filing ↗
- Section 08, David P. Schenkein. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 704,565. View filing ↗
- Section 08, Kathryn Guarini. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 701,544. View filing ↗
- Section 08, George D. Yancopoulos. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Leonard S. Schleifer. DEF 14A, filed 2026-04-24. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-05-01. Form 4, filed 2026-05-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Arthur F. Ryan 2026-07-02. Form 4, filed 2026-07-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-08-10. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-08-18. Form 4, filed 2026-08-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-08-19. Form 4, filed 2026-08-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marion McCourt 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-09-02. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marion McCourt 2026-09-03. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-10-14. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kathryn Guarini 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marion McCourt 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael S. Brown 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael S. Brown 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael S. Brown 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christopher Fenimore 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph LaRosa 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, George L. Sing 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christine A. Poon 2026-11-02. Form 4, filed 2026-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Murphy 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Huda Y. Zoghbi 2026-11-03. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jason Pitofsky 2026-11-04. Form 4, filed 2026-11-06. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-17. Item 5.07 · say-on-pay result. As reported: 93.33% (votes for as printed: 96,469,374). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-18. Item 5.07 · say-on-pay result. As reported: 93.29% (votes for as printed: 98,781,758). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-20. Item 5.07 · say-on-pay result. As reported: 95.03% (votes for as printed: 106,667,264). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,273,453 + equity 1,313,565 + all other 68,928 = 2,655,946, summed across the director compensation table rows.
- Eli Lilly and Company, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. View filing ↗
- AbbVie Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
- Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
- Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
- BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- Bristol-Myers Squibb Company, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. View filing ↗
- Vertex Pharmaceuticals Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. View filing ↗
- Merck & Co., Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Merck & Co., Inc.'s own proxy. As printed: 20,797,845. View filing ↗
- Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
- Regeneron Pharmaceuticals, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc's own proxy. As printed: 7,280,549. View filing ↗
- Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Bristol-Myers Squibb Company reciprocity. DEF 14A. Bristol-Myers Squibb Company names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Gilead Sciences, Inc. reciprocity. DEF 14A. Gilead Sciences, Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, BioMarin Pharmaceutical Inc. reciprocity. DEF 14A. BioMarin Pharmaceutical Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Amgen Inc. reciprocity. DEF 14A. Amgen Inc. names Regeneron Pharmaceuticals, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗